Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Botulinum toxin is a muscle-relaxing medication made from bacteria called clostridium botulinum. Commonly known as Botox, this is the drug use to smooth wrinkles. There are four types of botulinum toxin which includes OnabotulinumtoxinA, RimabotulinumtoxinB, AbobotulinumtoxinA and IncobotulinumtoxinA. These drugs also treat other problems, including a condition in which the neck muscles contract over and migraine headaches. Botulinum toxin acts as a neurotoxin. It binds to the nerve ending at the point where the nerve joins a muscle, blocking the release by the nerve of the chemical acetylcholine and preventing the muscle from contracting.
The rising demand for non-surgical cosmetic procedures and increasing demand foe botulinum toxin in the facial injectable procedure are the prominent factors leading to the growth of the botulinum toxin market globally. According to The International Society of Aesthetic Plastic Surgery there were 4,931,577 botulinum toxin cosmetic procedures carried out globally in 2016. Introduction of new products coupled with frequent FDA approvals for the products further boost the demand for botulinum toxin in the global market. For instance, in 2016, Ipsen S.A. received the U.S. Food and Drug Administration (FDA) approval for its Dysport (abobotulinumtoxinA) injection indicated for the treatment of paediatric lower limb (PLL) spasticity in children of age two years and older. In 2017, company received the FDA approval for same product to use in adults. However, risk associated with the use of botulinum toxin in cosmetic procedures and stringent government policies for the use of products in the United States and Europe may hamper the growth of the market over the forecast period.
The report analyses the botulinum toxin market on the basis of product type, application, end users and geography.
Based on product, the global botulinum toxin market is segmented into Type A and Type B. Currently three type A and one type B toxin are approved by the FDA for clinical use in the United States. The type A toxins are Botox produced by Allergan Inc., Xeomin from Merz Pharma, and Dysport from Ipsen. The type B toxin, Myobloc is produced by Solstice/US World Meds. The type A botulinum toxin holds the largest share in the global botulinum toxin market in 2018. Various products of type A botulinum toxin are commercially available in the market which includes leading brands such as Botox and Dysport. Botox has aesthetic application in moderate and severe glabellar lines removal and therapeutic application in treating severe primary axillary hyperidrosis, blepharospasm and cervical dystonia. Similarly, Xeomin is used for removal of glabellar lines and treatment of cervical dystonia and blepharospasm in some countries.
Furthermore, the botulinum toxin is used mostly for cosmetic and therapeutic treatments. The cosmetic segment is further bifurcated into crow’s feet, forehead lines, frown lines/glabellar, square jaw masseter and others. Others includes wrinkles of the lips, lower the upper lip, etc. Likewise, the therapeutic segment is divided into chronic migraine, muscle spasm, over reactive bladder, hyperhidrosis and others. Others include cervical dystonia, spasticity, etc. In 2018, the cosmetic segment dominated the global botulinum toxin market. Botulinum toxin is primarily used for cosmetic (aesthetic) application in improving the facial appearance and reducing signs of aging. It is used for treating frown lines, crow’s feet lines, and glabellar lines. Moreover, the therapeutic segment is anticipated to grow at a higher CAGR over the forecast period. Botulinum toxin is an effective treatment option for chronic cases of migraine, muscle spasm, over reactive bladder, and hyperhidrosis. Besides these, botulinum toxin has been found to be extremely effective in alleviating chronic cases of pelvic pain in women suffering from endometriosis.
The major end users of the botulinum toxin market are hospitals, specialty clinics and spas & beauty clinics. In 2018, the spas & beauty clinics segment dominated the global botulinum toxin market due to rising number of people opting for cosmetic procedures globally and establishments of spas & beauty clinics in developed and developing countries.
Geographically, the global botulinum toxin market is categorized into North America, Europe, Asia Pacific and Rest of the World. Rest of the world comprises of Latin America and Middle East & Africa. North America is expected to hold a dominant position in the global botulinum toxin market, owing to increasing trend of cosmetic procedures in the region. For instance, according to a report published by American Society of Plastic Surgeons in 2016, around US$ 16.4 billion was spent on cosmetic procedures in the U.S. and in 2017, around 7.2 million botulinum injections were used in the U.S. Asia Pacific is expected to exhibit the highest growth in the near future due to aging demographics and rising disposable income resulting in higher demand for anti-aging products. In addition, the growing social awareness regarding commercial availability of these products in Asia Pacific is anticipated to augment the growth of the market in the near future.
Key players of the global botulinum toxin market are Allergan, Daewoong Co.Ltd, HUGEL, Inc, Ipsen Pharma, Medy-Tox Inc, Merz Pharma, US WorldMeds, LLC, Hugh Source (International) Ltd., Revance Therapeutics, Inc, etc. The competition in the market is expected to intensify over the forecast period since several companies are now focusing on their research & development and new product launches. The global botulinum toxin market is dominated by few well established players such as Allergan, Ipsen Pharma, Merz Pharma, etc. Mergers, acquisitions and new product launches are the major strategies adopted by the key market players to reinforce their position in the global market.
Botulinum toxin is a product produced by naturally occurring Clostridium botulinum bacteria. The bacteria are found in soil and marine sediments. Botulinum toxin is a ‘blocking agent’ which inhibits the release of certain neurotransmitters, specifically acetylcholine, from the endings of the motor nerves. Through the decades, neurotoxins have been used for both medical indications ranging from headache to overactive bladder and cosmetic indications such as relaxing of glabellar wrinkles and crow’s feet. The report analyses the botulinum toxin market on the basis of product type, application, end users and geography. Based on product, the global botulinum toxin market is segmented into Type A and Type B. Furthermore, the botulinum toxin is used mostly for cosmetic and therapeutic. The cosmetic segment is further bifurcated into crow’s feet, forehead lines, frown lines/glabellar, square jaw masseter and others. Likewise, the therapeutic segment is divided into chronic migraine, muscle spasm, over reactive bladder, hyperhidrosis and others. The major end users of the botulinum toxin market are hospitals, specialty clinics and spas & beauty clinics. Geographically, the global botulinum toxin market is categorized into North America, Europe, Asia Pacific and Rest of the World. Rest of the world comprises of Latin America and Middle East & Africa. North America is expected to hold a dominant position in the global botulinum toxin market, owing to increasing trend of cosmetic procedures in the region. Key players of the global botulinum toxin market are Allergan, Daewoong Co.Ltd, HUGEL, Inc, Ipsen Pharma, Medy-Tox Inc, Merz Pharma, US WorldMeds, LLC, Hugh Source (International) Ltd., Revance Therapeutics, Inc, etc.
Why to buy this report:
